CVS Health Corporation (NYSE:CVS) had its price target upped by research analysts at Jefferies Group LLC from $82.00 to $86.00 in a report released on Friday, Marketbeat reports. The brokerage currently has a “hold” rating on the pharmacy operator’s stock. Jefferies Group LLC’s price target indicates a potential upside of 3.40% from the stock’s current price.

CVS has been the topic of several other research reports. Vetr downgraded CVS Health Corporation from a “strong-buy” rating to a “buy” rating and set a $88.97 price objective on the stock. in a research note on Monday, June 12th. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of CVS Health Corporation in a research note on Sunday, September 10th. Citigroup Inc. dropped their price objective on CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating on the stock in a research note on Thursday, August 17th. Finally, BidaskClub downgraded CVS Health Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $90.35.

Shares of CVS Health Corporation (NYSE:CVS) traded up 0.64% on Friday, hitting $83.17. The stock had a trading volume of 7,483,220 shares. The firm has a 50 day moving average price of $78.80 and a 200 day moving average price of $78.96. CVS Health Corporation has a one year low of $69.30 and a one year high of $90.85. The company has a market capitalization of $84.55 billion, a P/E ratio of 16.57 and a beta of 0.92.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. The company had revenue of $45.69 billion for the quarter, compared to the consensus estimate of $45.36 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.32 EPS. On average, equities research analysts predict that CVS Health Corporation will post $5.88 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/15/jefferies-group-llc-boosts-cvs-health-corporation-cvs-price-target-to-86-00.html.

In other news, Director Richard J. Swift sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total value of $199,050.00. Following the completion of the transaction, the director now owns 3,258 shares in the company, valued at approximately $259,401.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David M. Denton sold 237,078 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the transaction, the chief financial officer now owns 141,096 shares of the company’s stock, valued at approximately $11,238,296.40. The disclosure for this sale can be found here. Insiders sold a total of 370,510 shares of company stock valued at $29,460,266 in the last 90 days. 0.61% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pathstone Family Office LLC grew its holdings in shares of CVS Health Corporation by 341.0% in the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after acquiring an additional 982 shares in the last quarter. Fieldpoint Private Securities LLC grew its holdings in shares of CVS Health Corporation by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares in the last quarter. Mercer Capital Advisers Inc. bought a new position in shares of CVS Health Corporation in the 1st quarter valued at about $118,000. TB Alternative Assets Ltd. acquired a new stake in CVS Health Corporation in the 2nd quarter valued at about $121,000. Finally, Gemmer Asset Management LLC lifted its stake in CVS Health Corporation by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 81.55% of the company’s stock.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.